RE:RE:RE:Unfortunate timing - Nicholls article on RVX - 09/15I had a couple of posts on the other board linked
here and
here that talked about this ASSURE article and another recent review.
ASSURE had to be published. This particular article was simply the Cleveland Clinic obligitory publication of the original primary and secondary endpoints. It mainly focused on the IVUS PAV and TAV data and change in apoAI and HDL. What is disappointing is that this article didn't mention MACE as best as I could tell from the abstract. It might mention it in the full text that I can't access. 5-point MACE was a pre-defined secondary endpoint. And as we know, the MACE data was the most exciting thing to come out of SUSTAIN/ASSURE and the basis for the upcoming Phase 3 BETonMACE!